Share on StockTwits

Verastem (NASDAQ:VSTM) Chairman Christoph H. Westphal purchased 2,000 shares of Verastem stock on the open market in a transaction that occurred on Wednesday, May 14th. The shares were purchased at an average cost of $7.56 per share, for a total transaction of $15,120.00. Following the transaction, the chairman now directly owns 700,264 shares of the company’s stock, valued at approximately $5,293,996. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Verastem (NASDAQ:VSTM) traded down 0.13% on Thursday, hitting $7.64. 104,369 shares of the company’s stock traded hands. Verastem has a one year low of $7.10 and a one year high of $18.82. The stock’s 50-day moving average is $9.08 and its 200-day moving average is $11.48. The company’s market cap is $197.4 million.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.08. Analysts expect that Verastem will post $-1.92 EPS for the current fiscal year.

Separately, analysts at Deutsche Bank initiated coverage on shares of Verastem in a research note on Tuesday, May 6th. They set a “buy” rating and a $14.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $20.44.

Verastem, Inc is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.